Spots Global Cancer Trial Database for Study of BMS-663513 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of BMS-663513 in Patients With Advanced Cancer
Official Title: A Phase I/II, Ascending Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients With Metastatic or Locally Advanced Solid Malignancies
Study ID: NCT00309023
Conditions
Interventions
Study Description
Brief Summary: This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City Of Hope National Medical Center, Duarte, California, United States
Yale University School Of Medicine, New Haven, Connecticut, United States
Indiana University Cancer Center, Indianapolis, Indiana, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Local Institution, Toronto, Ontario, Canada
Local Institution, Bordeaux, , France
Local Institution, Paris, , France
Local Institution, Paris, , France
Local Institution, Saint Herblain, , France
Local Institution, Villejuif Cedex, , France
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
